LVTX Penghasilan resik perusahaan Lava Tx

LAVA Therapeutics N.V. (LVTX) maintains resilience through partnerships with industry behemoths and its Gammabody platform for combating tumors. Reviewing the company's operating profit on GURU.Markets reveals that the figure stands at -0.02. Growth potential is based on the development of T-cell therapies, while a high reputation within the biotech community strengthens investor confidence in the brand's future commercial success.

LVTX lavatherapeutics.com: Penghasilan resik ing interval 04.07.2022 - 06.12.2025

Rincian metrik keuangan lan pasar lavatherapeutics.com (LVTX)

- rega saham lan konsensus proyeksi valuasi:

Bagan rega LAVA Therapeutics|LVTX - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar LVTX|LVTX - Nilai Perusahaan

- data ekuitas miturut neraca:

Nilai Buku Siji Saham LAVA Therapeutics|LVTX - Aset Bersih Perusahaan|Koefisien Nilai Pasar marang Nilai Buku lavatherapeutics.com|LVTX - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi LAVA Therapeutics N.V.|LVTX - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal LAVA Therapeutics|LVTX - Utang perusahaan|Utang marang nilai buku LVTX|LVTX - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan LAVA Therapeutics|Rasio cepet lavatherapeutics.com

- data bathi bisnis lan rasio investasi:

LVTX - Bathi resik perusahaan

Analisis dhasar perusahaan:LVTX, Lava Tx

This indicator reflects the daily dynamics of net profit minus operating expenses, allowing for an objective assessment of the issuer's financial stability by monitoring regulatory deviations. Analyzing the total financial result of LAVA Therapeutics N.V. (LVTX) serves as a tool for long-term portfolio stress testing, which is critical for LAVA Therapeutics N.V. (LVTX), as its bispecific oncology drugs are in the pre-commercial stage of development in partnership with pharmaceutical behemoths.

Pesaing utama